Nature Communications (Dec 2022)
Non-classical ferroptosis inhibition by a small molecule targeting PHB2
- Wei Yang,
- Bo Mu,
- Jing You,
- Chenyu Tian,
- Huachao Bin,
- Zhiqiang Xu,
- Liting Zhang,
- Ronggang Ma,
- Ming Wu,
- Guo Zhang,
- Chong Huang,
- Linli Li,
- Zhenhua Shao,
- Lunzhi Dai,
- Laurent Désaubry,
- Shengyong Yang
Affiliations
- Wei Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Bo Mu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Jing You
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Chenyu Tian
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Huachao Bin
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Zhiqiang Xu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Liting Zhang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Ronggang Ma
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Ming Wu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Guo Zhang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Chong Huang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Linli Li
- Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University
- Zhenhua Shao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Lunzhi Dai
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- Laurent Désaubry
- Regenerative Nanomedicine Laboratory (UMR1260), INSERM-University of Strasbourg, Center of Research in Biomedicine of Strasbourg (CRBS)
- Shengyong Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
- DOI
- https://doi.org/10.1038/s41467-022-35294-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
Ferroptosis is a promising therapeutic target for a variety of diseases, but a majority of known ferroptosis inhibitors belong to either antioxidants or iron chelators. Here, the authors discover a new non-classical small molecule inhibitor that is a PHB2 binder and show it ameliorates liver damage in an acute liver injury model.
